Dragonfly’s TrinKET-enhancing cytokine platform sees early win with $475M BMS deal 

Dragonfly has struck another deal with BMS for nearly half a billion dollars up front covering a clinical IL-12 program designed to complement its NK cell engager technology and other immunotherapies. 

The biotech will receive $475 million in upfront payments in exchange for an exclusive, global license to DF6002, and is eligible to receive undisclosed development, regulatory and commercial milestones, plus up to 24% royalties. ...